Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting

Basit Öğe Kaydı
dc.contributor.authorGokalp, Osman
dc.contributor.authorGunes, Arzu
dc.contributor.authorCam, Hakan
dc.contributor.authorCure, Erkan
dc.contributor.authorAydin, Osman
dc.contributor.authorTamer, Mehmet Numan
dc.contributor.authorScordo, Maria Gabriella
dc.date.accessioned2024-04-24T15:59:49Z
dc.date.available2024-04-24T15:59:49Z
dc.date.issued2011
dc.departmentDicle Üniversitesien_US
dc.description.abstractTo evaluate the impact of polymorphisms in the cytochrome P450 (CYP) 2C9, 2C19 and 2C8 genes on the risk of mild hypoglycaemic attacks in patients treated with sulphonylureas. One hundred and eight type 2 diabetic patients (50 men, 58 women), treated with oral antidiabetics, including at least one from the sulphonylurea group (glimepiride n = 50, gliclazide n = 46, or glipizide n = 12) for 3 months or longer, were included in the study. Symptoms of hypoglycaemia (sweating, tremor, anxiety and palpitations) during a 3 month period were recorded and confirmed by home glucose measurements. Gender, age, body mass index, creatinine clearance, HbA1c, oral antidiabetic dose and concomitant medication were assessed together with functional CYP2C9, CYP2C19 and CYP2C8 polymorphisms, analysed by real-time PCR methods. Fifteen patients (eight men, seven women) reported hypoglycaemia symptoms which were validated by their home glucose measurements (< 70 mg/dl). Heterozygosity and homozygosity for CYP2C9 variant alleles (*2 or *3) tended to be more frequent among patients who reported hypoglycaemic attacks (60 and 7%) than those who did not (39 and 3%). Similarly, the CYP2C8*1/*3 genotype tended to be more frequent in patients with (47%) than without (27%) hypoglycaemia, while no such trend was observed for CYP2C19 variants. However, only in the gliclazide group a significant association between CYP2C9 genotype and hypoglycaemic attacks was observed (P = 0.035). None of the other covariates showed any significant association with the risk of hypoglycaemic attacks. CYP2C9 polymorphisms leading to decreased enzyme activity show a modest impact on the risk of mild hypoglycaemia attacks during oral antidiabetic treatment, with a significant association in patients treated with gliclazide.en_US
dc.description.sponsorshipSwedish Research Council; Scientific and Technological Research Council of Turkeyen_US
dc.description.sponsorshipThe study has been financed by grants from the Swedish Research Council and the Scientific and Technological Research Council of Turkey.en_US
dc.identifier.doi10.1007/s00228-011-1078-4
dc.identifier.endpage1229en_US
dc.identifier.issn0031-6970
dc.identifier.issn1432-1041
dc.identifier.issue12en_US
dc.identifier.pmid21691805en_US
dc.identifier.scopus2-s2.0-82455167877en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1223en_US
dc.identifier.urihttps://doi.org/10.1007/s00228-011-1078-4
dc.identifier.urihttps://hdl.handle.net/11468/14270
dc.identifier.volume67en_US
dc.identifier.wosWOS:000297127000003en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofEuropean Journal of Clinical Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSulphonylureaen_US
dc.subjectHypoglycaemic Attacksen_US
dc.subjectCyp2c9en_US
dc.subjectCyp2c19en_US
dc.subjectCyp2c8en_US
dc.subjectPolymorphismen_US
dc.subjectGliclazideen_US
dc.subjectGlimepirideen_US
dc.subjectGlipizideen_US
dc.titleMild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical settingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu